Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.
MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23
Frederique Penault-Llorca explains that gene fusions are rare but present in a high number of cancers and several of them are already targetable. From an array of gene fusions, she details on NTRK family which requires a specific approach regarding detection because of an agnostic biomarker’s nature.
She details about techniques for detection of alterations and the recommendations for testing algorithm to apply.
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.
